 Biopharma deal-making is expected to pick up in 2021 after its slump in 2020, with a good example being AstraZenecas AZN nearly 40 billion purchase of Alexion Pharmaceuticals ALXN, which was announced on Dec. 12. Industry observers are already predicting that, after the down year that was 2020, MA activity will return to pre-Covid heights, according to an article in FiercePharma. 